Oncolytics Biotech (ONC) Stock Forecast & Price Target

C$1.40 -0.08 (-5.41%)

(As of 11/20/2024 ET)

Oncolytics Biotech - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 1 Analyst Ratings

Sell
0

Hold
0

Buy
1

Based on 1 Wall Street analysts who have issued ratings for Oncolytics Biotech in the last 12 months, the stock has a consensus rating of "Buy." Out of the 1 analysts, 1 has given a buy rating for ONC.

Consensus Price Target

C$3.50
150.00% Upside

According to the 1 analysts' twelve-month price targets for Oncolytics Biotech, the average price target is C$3.50. The highest price target for ONC is C$3.50, while the lowest price target for ONC is C$3.50. The average price target represents a forecasted upside of 150.00% from the current price of C$1.40.

Get the Latest News and Ratings for ONC and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Oncolytics Biotech and its competitors.

ONC Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)	3 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	C$3.50	C$3.50	C$3.00	C$9.00
Forecasted Upside	150.00% Upside	100.00% Upside	123.88% Upside	309.09% Upside
Consensus Rating	Buy	Buy	Buy	Buy

Trump said you could learn something from this man (Ad)

Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement.

Here’s everything you need to know.

ONC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ONC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Oncolytics Biotech Stock vs. The Competition

Type	Oncolytics Biotech	Medical Companies
Consensus Rating Score	3.00	2.80
Consensus Rating	Buy	Moderate Buy
News Sentiment Rating	Neutral News See Recent ONC News	Neutral News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/14/2024	Raymond James 4 of 5 stars	M. Freeman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy
1/12/2024	Cantor Fitzgerald 3 of 5 stars	L. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
5/24/2023	Jonestrading 1 of 5 stars		Set Target	Buy	C$9.00	+240.91%
3/14/2023	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Trucchio Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 08:40 AM ET.

ONC Forecast - Frequently Asked Questions

: According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for Oncolytics Biotech is C$3.50, with a high forecast of C$3.50 and a low forecast of C$3.50.
: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last twelve months. There is currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ONC shares.
: According to analysts, Oncolytics Biotech's stock has a predicted upside of 150.00% based on their 12-month stock forecasts.
: Over the previous 90 days, Oncolytics Biotech's stock had 1 upgrade by analysts.
: Oncolytics Biotech has been rated by research analysts at Raymond James in the past 90 days.
: Analysts like Oncolytics Biotech more than other "medical" companies. The consensus rating for Oncolytics Biotech is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ONC compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)

Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…

Get Your Free Gold Guide

This page (TSE:ONC) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncolytics Biotech (ONC) Stock Forecast & Price Target